Anti-CD38 nanobodies as theranostic agents for multiple myeloma

被引：0
|
作者：
Duray, Elodie [1 ]
Lejeune, Margaux [1 ]
Dumoulin, Mireille [1 ]
D'Huyvetter, Matthias [2 ]
Caers, Jo [3 ]
机构：
[1] ULiege, Liege, Belgium
[2] Vrije Univ Brussel, Brussels, Belgium
[3] CHU Liege, Liege, Belgium
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-044
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [21] Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
    Zannetti, Beatrice Anna
    Faini, Angelo Corso
    Massari, Evita
    Geuna, Massimo
    Maffini, Enrico
    Poletti, Giovanni
    Cerchione, Claudio
    Martinelli, Giovanni
    Malavasi, Fabio
    Lanza, Francesco
    CELLS, 2020, 9 (12) : 1 - 13
  • [22] SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA (MM) REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORS, AND ANTI-CD38
    Gener Ricos, G.
    Abril Sabater, L.
    Ibarra Fernandez, G.
    Franch Sarto, M.
    Santos Gomez, M.
    Canamero Giro, E.
    Comes Escoda, M.
    Espasa Perez, A.
    De La Fuente Montes, C.
    Huguet Mas, M.
    Quintela Vilchez, D.
    Ribera-Santasusana, J. M.
    Oriol Rocafiguera, A.
    HAEMATOLOGICA, 2019, 104 : 9 - 10
  • [23] Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab
    Thirkettle, Sally
    Russell, Joanne
    Wilson, Sarah
    Ganijee, Tasneem
    Kulkarni, Samar
    Cavet, Jim
    Monaghan, Phillip J.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2020, 57 (02) : 178 - 181
  • [24] Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure
    Zamanillo, Irene
    De la Puerta, Rosalia
    Gil, Rodrigo
    Poza, Maria
    De la Puerta, Rodrigo
    Alonso, Rafael
    Cedena, Teresa
    Calbacho, Maria
    Ayala, Rosa
    Martinez-Lopez, Joaquin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S164 - S165
  • [25] Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma
    Rabut, Elodie
    Castro-Fernandez, Annabelle
    Le Gall, Virginie
    Meknache, Nihad
    ANNALES DE BIOLOGIE CLINIQUE, 2017, 75 (03) : 351 - 355
  • [26] Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
    Zamagni, Elena
    Tacchetti, Paola
    Pantani, Lucia
    Cavo, Michele
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) : 423 - 435
  • [27] Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
    De Novellis, Danilo
    Fontana, Raffaele
    Giudice, Valentina
    Serio, Bianca
    Selleri, Carmine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [28] Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
    Horenstein, Alberto L.
    Faini, Angelo C.
    Morandi, Fabio
    Ortolan, Erika
    Storti, Paola
    Giuliani, Nicola
    Richardson, Paul G.
    Malavasi, Fabio
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [29] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Faini, Angelo Corso
    Castella, Barbara
    Horenstein, Alberto
    Morandi, Fabio
    Malavasi, Fabio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [30] ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER
    Pimentel, Villar M. A.
    Anguita, Arance M. M.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2021, 106 (10) : 337 - 337
12345